PubRank

Marion Kiechle

Author PubWeight™ 84.61‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010 5.48
2 Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009 2.47
3 First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT. Eur J Nucl Med Mol Imaging 2010 2.07
4 SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis 2008 1.84
5 Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 2004 1.49
6 A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol 2012 1.44
7 Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study. BMC Cancer 2006 1.38
8 Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 2009 1.37
9 Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst 2008 1.36
10 Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One 2008 1.35
11 Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005 1.34
12 FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006 1.31
13 Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Hum Mutat 2011 1.29
14 Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res 2004 1.29
15 The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat 2007 1.24
16 Aurora kinases A and B and familial breast cancer risk. Cancer Lett 2006 1.24
17 The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 2012 1.22
18 Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004 1.17
19 Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003 1.14
20 MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases. Hum Mutat 2008 1.11
21 Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 2005 1.09
22 Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis 2006 1.07
23 Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002 1.04
24 Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients. Int J Cancer 2010 1.03
25 Freehand SPECT for image-guided sentinel lymph node biopsy in breast cancer. Eur J Nucl Med Mol Imaging 2013 1.01
26 Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010 1.01
27 Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 2004 1.00
28 The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer. Carcinogenesis 2006 1.00
29 On the difference of micronucleus frequencies in peripheral blood lymphocytes between breast cancer patients and controls. Mutagenesis 2006 0.98
30 Body piercing affecting laparoscopy: perioperative precautions. J Am Assoc Gynecol Laparosc 2004 0.97
31 Extended indications for nipple-sparing mastectomy. Breast J 2011 0.97
32 Twenty-five simple ways to increase insufflation performance and patient safety in laparoscopy. J Am Assoc Gynecol Laparosc 2004 0.96
33 Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 2003 0.96
34 An automated scoring procedure for the micronucleus test by image analysis. Mutagenesis 2004 0.95
35 Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. Onkologie 2011 0.95
36 Subcutaneous mastectomy with conservation of the nipple-areola skin: broadening the indications. Ann Surg 2009 0.93
37 Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol Chem 2012 0.92
38 Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr Relat Cancer 2007 0.92
39 Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer 2012 0.92
40 Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer). Breast Care (Basel) 2009 0.92
41 BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study. BMC Cancer 2007 0.92
42 Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res 2012 0.92
43 Breast ductoscopy with a 0.55-mm mini-endoscope for direct visualization of intraductal lesions. J Minim Invasive Gynecol 2005 0.92
44 Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res 2008 0.91
45 Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis 2006 0.91
46 Three-dimensional model for gas flow, resistance, and leakage-dependent nominal pressure maintenance of different laparoscopic insufflators. J Minim Invasive Gynecol 2006 0.90
47 Non-invasive tracking of human haemopoietic CD34(+) stem cells in vivo in immunodeficient mice by using magnetic resonance imaging. Eur Radiol 2010 0.88
48 The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. Breast Cancer Res Treat 2006 0.88
49 Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol 2009 0.88
50 Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. Breast Cancer Res Treat 2008 0.87
51 High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism. Int J Oncol 2003 0.86
52 Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. C R Biol 2007 0.86
53 Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. Clin Cancer Res 2007 0.85
54 Association of the NuMA region on chromosome 11q13 with breast cancer susceptibility. Proc Natl Acad Sci U S A 2005 0.85
55 Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. Arch Gynecol Obstet 2013 0.84
56 Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. Biol Chem 2014 0.84
57 Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer. Oncology 2011 0.83
58 MR-guided intervention in women at high hereditary risk of breast cancer due to both family and personal history of breast cancer. Breast J 2007 0.83
59 High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells. Int J Cancer 2012 0.83
60 Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 2002 0.83
61 Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: an update. Onkologie 2006 0.82
62 Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer. PLoS One 2013 0.82
63 Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer. Onkologie 2011 0.82
64 Physician-based active cost management of oncological therapies reducing pharmaceutical costs by 83.4% in two years without leaving standard of care. Onkologie 2005 0.82
65 Mastitis nonpuerperalis after nipple piercing: time to act. Int J Fertil Womens Med 2003 0.82
66 An economic model to reduce the cost of chemotherapy for gynecologic cancer. Int J Fertil Womens Med 2005 0.81
67 Demographic and psychosocial factors associated with risk perception for breast cancer. Oncol Rep 2005 0.81
68 Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer. Oncology 2011 0.81
69 Genetic polymorphisms in DPF3 associated with risk of breast cancer and lymph node metastases. J Carcinog 2005 0.81
70 A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding. Clin Biochem 2011 0.81
71 Axillary Dissection with Access Minimized (ADAM): a new technique for lymph node dissection in conservative surgery for breast cancer. Int J Fertil Womens Med 2003 0.79
72 Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome. Gynecol Oncol 2012 0.78
73 Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. Int J Cancer 2014 0.77
74 Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine. Cell Biochem Funct 2011 0.77
75 mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer. Biol Chem 2011 0.77
76 Short-term and long-term outcome of radiological-guided insertion of central venous access port devices implanted at the forearm: a retrospective monocenter analysis in 1704 patients. Eur Radiol 2014 0.76
77 Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat 2015 0.76
78 Genetic variation in the major mitotic checkpoint genes does not affect familial breast cancer risk. Breast Cancer Res Treat 2007 0.76
79 Carbon dioxide gas heating inside laparoscopic insufflators has no effect. JSLS 2005 0.75
80 Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer. Breast Care (Basel) 2012 0.75
81 Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion. Breast Care (Basel) 2012 0.75
82 Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer. Biol Chem 2016 0.75
83 Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiol Oncol 2013 0.75
84 Development of a thinner and more flexible type of minihysteroscope with a controlled 90-degree bendable tip for vision-guided endometrium biopsy. J Minim Invasive Gynecol 2005 0.75
85 Allelic loss analysis by denaturing high-performance liquid chromatography and electrospray ionization mass spectrometry. Hum Mutat 2007 0.75
86 Primary metastatic leiomyosarcoma of the fallopian tube: a rare case report. Onkologie 2010 0.75
87 Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer. Biol Chem 2017 0.75
88 G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients. Onkologie 2006 0.75
89 Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer. Breast 2013 0.75
90 Sarcopenia in Advanced Serous Ovarian Cancer. Int J Gynecol Cancer 2016 0.75
91 Changing the intraoperative nodal status of a breast cancer patient using freehand SPECT for sentinel lymph node biopsy. Clin Nucl Med 2014 0.75